EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer

Yiyi Xu iD, Jiwei Gao, Na Wang, Jan Zedenius iD, Inga-Lena Nilsson, Weng-Onn Lui, Dawei Xu, C Christofer Juhlin, Catharina Larsson iD, Ninni Mu iD

The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · 693-705

DOI: 10.1210/clinem/dgae589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 26.08.2024. Verfasst von Yiyi Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 64, Sweden. Hauptthemen laut MEDLINE: Telomerase, Proto-Oncogene Proteins B-raf, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Cancer Society, Swedish Research Council, Stockholm County Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma (PTC) have a synergistic effect on prognosis. This effect is believed to arise from MAPK activation triggered by BRAFV600E, leading to the upregulation of ETS transcription factors that bind to the mutant TERT promoter.

Objectives

To explore the role of ETS factors in relation to clinical features, BRAFV600E, and TERT promoter mutations in PTC.

Design

Transcriptomic data for 28 ETS factors were analyzed in the PTC cohort of The Cancer Genome Atlas (n = 399) and subsequently validated in a local cohort (n = 93). In vitro experiments were performed to investigate the regulatory role in relation to BRAFV600E and TERT expression.

Results

The Cancer Genome Atlas identified ETS1, ERG, FLI1, GABPA, EHF, ETV6, and SPDEF as differentially expressed genes between stages I + II and III + IV. In both cohorts, EHF was consistently associated with adverse clinical features, BRAFV600E and TERT promoter mutation/expression. Notably, in BRAFV600E mutated PTC, high EHF expression was associated with shorter disease-free survival. Cases harboring concurrent BRAFV600E, TERT promoter mutations, and high EHF expression exhibited the shortest disease-free survival. In cells harboring concurrent BRAFV600E and TERT promoter mutation, overexpression of EHF significantly increased TERT expression, whereas knockdown or pharmacological inhibition of BRAF significantly decreased both EHF and TERT expression. In addition, chromatin immunoprecipitation and quantitative PCR analysis suggested a potential binding of EHF in TERT promoter mutant cells but not in TERT promoter wild-type cells.

Conclusion

The ETS transcription factor EHF is associated with poor prognosis in PTC. This is potentially mediated by BRAF-induced upregulation of EHF, which in turn increases TERT expression in TERT promoter mutated cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid NeoplasmsHumansFemaleMalePromoter Regions, GeneticGene Expression Regulation, NeoplasticMiddle AgedMutationPrognosisAdultProto-Oncogene Proteins c-etsCell Line, Tumor

Stichwörter der Autor:innen

BRAFV600EEHFTERT promoter mutationprognosisthyroid carcinoma

Substanzen

TelomeraseProto-Oncogene Proteins B-rafTERT protein, humanBRAF protein, humanProto-Oncogene Proteins c-ets

Autor:innen und Institutionen

  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm SE-171 64, Sweden.
  • The Cancer Hospital of the University of Chinese Academy of Sciences, (Zhejiang Cancer Hospital), Hangzhou 310022, China.
  • Department of Medicine-Huddinge, Karolinska Institutet, Stockholm SE-141 83, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm SE-171 76, Sweden.
  • Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm SE-171 64, Sweden.
  • Department of Medicine-Solna, Karolinska Institutet, Stockholm SE-171 76, Sweden.

ORCID-Profile: Yiyi Xu, Jan Zedenius, Catharina Larsson, Ninni Mu

Förderung

  • Swedish Cancer Society
  • Swedish Research Council
  • Stockholm County Council
  • Karolinska Institutet
  • China Scholarship Council

Zitieren

APA

Xu, Y., Gao, J., Wang, N., Zedenius, J., Nilsson, I. L., Lui, W. O., Xu, D., Juhlin, C. C., Larsson, C., & Mu, N. (2025). BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 110(3), 693-705. https://doi.org/10.1210/clinem/dgae589

Vancouver

Xu Y, Gao J, Wang N, Zedenius J, Nilsson IL, Lui WO, et al. BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):693-705. doi:10.1210/clinem/dgae589

BibTeX
@article{Xu2025,
  author = {Xu, Yiyi and Gao, Jiwei and Wang, Na and Zedenius, Jan and Nilsson, Inga-Lena and Lui, Weng-Onn and Xu, Dawei and Juhlin, C Christofer and Larsson, Catharina and Mu, Ninni},
  title = {BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {3},
  pages = {693--705},
  doi = {10.1210/clinem/dgae589}
}
Kostenlos starten →